Leukogene Therapeutics Welcomes Dr. Sandeep Gupta as CEO
Leukogene Therapeutics Inc. announces the appointment of Dr. Sandeep Gupta as Chief Executive Officer. Dr. Gupta, with over 25 years of experience in the pharmaceutical industry, brings a wealth of knowledge and leadership to the company. His history includes founding Asana BioSciences, where he focused on innovative oncology and immunology therapies.
Dr. Gupta's Impressive Background
Dr. Gupta's notable achievements include successfully discovering and advancing novel drug candidates to clinical development, particularly in oncology. At Asana BioSciences, he led private financing efforts and out-licensed multiple assets, significantly impacting the company's growth. Recently, he served as the CEO of Kashiv BioSciences, contributing to the development and manufacturing of biosimilars.
Vision for the Future
Dr. Lawrence Olanoff, Chairman of the Board at Leukogene, expressed confidence in Dr. Gupta's capabilities, stating that his experience is critical for the company's current stage. The team believes that his leadership will guide Leukogene toward achieving its ambitious goals.
Innovative Cancer Treatments
Co-founders Dr. Nathan Dolloff and Dr. Frank Marcoux highlighted Dr. Gupta's extensive hands-on experience in oncology and immunology. They are optimistic that his visionary approach will help deliver the promising M2T™ immunotherapies to cancer patients.
Dr. Gupta’s Enthusiasm for the Role
Dr. Gupta himself expressed excitement about joining Leukogene, where he aims to work closely with the existing team to promote the development of their M2T™ immunotherapy candidates. This innovative approach focuses on enhancing immune responses against challenging cancer types.
Academic and Professional Credentials
Before his leadership roles, Dr. Gupta held significant positions in discovery and early development at Endo Health Solutions and served as Head of Discovery and Pharmacology at Forest Laboratories. Additionally, he has academic experience from prestigious institutions, including the University of Pennsylvania and Boston University Schools of Medicine.
Educational Background
Dr. Gupta earned both his Bachelor and Master of Pharmaceutical Sciences from the Indian Institute of Technology, Banaras Hindu University, and a Ph.D. in Pharmacology from Northeastern University in Boston.
About Leukogene Therapeutics
Leukogene Therapeutics, spun out from the Medical University of South Carolina, focuses on developing cutting-edge oncology therapies. The company is recognized for its innovative M2T™ immunotherapy, which combines tumor-associated antigens with major histocompatibility complex II (MHCII) targeting proteins.
M2T™ Immunotherapy Insights
The M2T™ immunotherapy is designed to harness the body’s natural immune response, showcasing strong immunogenicity through MHCII presentation. The company's candidates have shown promise in preclinical models for challenging cancers such as acute myeloid leukemia and pancreatic ductal adenocarcinoma.
Industry Recognition
Leukogene is part of the NCI and SCRA SC Launch portfolio, reflecting its commitment to creating impactful therapies for cancer patients. With Dr. Gupta at the helm, the company is poised to make significant strides in the oncology realm.
Frequently Asked Questions
Who is Dr. Sandeep Gupta?
Dr. Sandeep Gupta is the newly appointed Chief Executive Officer of Leukogene Therapeutics, with over 25 years of experience in the pharmaceutical industry.
What is M2T™ immunotherapy?
M2T™ is an innovative immunotherapy aimed at harnessing immune responses against difficult-to-treat cancers through a unique combination of tumor-associated antigens and targeting proteins.
What companies has Dr. Gupta previously worked for?
Dr. Gupta has held significant positions at Asana BioSciences, Kashiv BioSciences, Endo Health Solutions, and Forest Laboratories, among others.
What is Leukogene Therapeutics' main focus?
Leukogene Therapeutics focuses on developing advanced immunotherapy treatments targeting hard-to-treat cancers.
What are the expectations for Dr. Gupta's leadership at Leukogene?
There is confidence that Dr. Gupta's experience and vision will lead Leukogene to achieve its objectives and enhance its impact in the oncology space.
